FDA Sanctions Patrick Soon-Shiong Over Misleading Cancer Drug Claims

The FDA’s recent warning to Patrick Soon-Shiong, the billionaire founder of ImmunityBio, represents a significant escalation in the agency’s oversight of executive communications. By flagging misleading claims made during a podcast, the FDA is signaling that the informal nature of digital media does not exempt pharmaceutical leaders from strict promotional guidelines. This move underscores the precarious balance between a high-profile founder’s public persona and the rigid regulatory framework governing drug efficacy claims. The warning specifically targets statements that suggested ImmunityBio’s bladder cancer drug could treat conditions beyond its FDA-approved indications, a practice known as off-label promotion.

At the heart of the dispute is ImmunityBio’s bladder cancer therapy, which received FDA approval for specific indications. However, Soon-Shiong’s public comments suggested the drug possessed broader therapeutic potential, effectively crossing the line into off-label promotion. For the FDA’s Office of Prescription Drug Promotion (OPDP), such statements are particularly egregious when they come from a physician-executive whose medical credentials lend an air of undue authority to unverified claims. This incident mirrors previous enforcement actions where the agency targeted celebrity endorsements, but it adds a new layer of complexity by targeting the company’s primary benefactor and visionary.

“

The FDA’s recent warning to Patrick Soon-Shiong, the billionaire founder of ImmunityBio, represents a significant escalation in the agency’s oversight of executive communications.

The legal implications for ImmunityBio are multifaceted. Beyond the immediate reputational damage, the company faces the risk of a Warning Letter or Untitled Letter evolving into more severe enforcement, including civil monetary penalties or a consent decree if the behavior persists. Furthermore, such regulatory rebukes often serve as a catalyst for shareholder derivative lawsuits, as investors may argue that executive misconduct has jeopardized the company’s valuation and regulatory standing. For the broader RegTech and legal compliance industry, this case serves as a definitive case study in the necessity of social media and podcasting compliance protocols for C-suite executives.

Looking ahead, the biotech sector must anticipate a more aggressive FDA presence in the digital ecosystem. As founders increasingly use direct-to-consumer platforms to build brand equity, the boundary between visionary leadership and illegal promotion is becoming a primary battleground for regulatory compliance. Legal departments will likely need to implement pre-clearance requirements for all executive public appearances, regardless of the perceived informality of the venue. The ImmunityBio case proves that in the eyes of federal regulators, a podcast microphone is just as formal—and just as regulated—as a television advertisement or a medical journal.